] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.LLC Purchase Agreement • November 13th, 2017 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • Delaware
This LLC Purchase Agreement (the “Agreement”) is made and entered into as of August 31, 2017, by and among: Saol International Limited, a Bermuda company (“Purchaser”), Aptevo BioTherapeutics LLC, a Delaware limited liability company (“Seller”), and Aptevo Therapeutics Inc., a Delaware corporation (“ATI”), and Venus BioTherapeutics Sub LLC, a Delaware limited liability company (the “Company”). Seller and ATI are collectively referred to as the “Seller Parties”. Certain capitalized terms used in this Agreement are defined in Exhibit A.
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • November 13th, 2017 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • New York
This Collaboration and Option Agreement (this “Agreement”) is entered into as of this 20th day of July, 2017 (the “Effective Date”), by and between Aptevo Research and Development LLC, a limited liability company existing under the laws of Delaware, having a place of business at 2401 4th Avenue, Suite 1050, Seattle, WA 98121 USA (“Aptevo”), and Alligator Bioscience AB, a company existing under the laws of Sweden, having a place of business at Medicon Village, 223 81 Lund, Sweden (“Alligator”). Each of Aptevo and Alligator may be referred to herein individually as a “Party” and collectively as the “Parties.”
